Literature DB >> 24312850

Development and application of an HPLC method for erlotinib protein binding studies.

Soheila Bolandnazar1, Adeleh Divsalar, Hadi Valizadeh, Arash Khodaei, Parvin Zakeri-Milani.   

Abstract

PURPOSE: The aim of the present study was to develop a simple and rapid reversed-phase high performance liquid chromatographic method with UV detection for erlotinib hydrochloride quantification, which is applicable for protein binding studies.
METHODS: Ultrafilteration method was used for protein binding study of erlotinib hydrochloride. For sample analysis a simple and rapid reversed-phase high performance liquid chromatographic method with UV detection at 332 nm was developed. The mobile phase was a mixture of methanol, acetonitril and potassium dihydrogen phosphate buffer (15:45:40 %v/v) set at flow rate of 1.3 ml/min.
RESULTS: The run time for erlotinib hydrochloride was approximately 6 minutes. The calibration curve was linear over the range of 320-20000 ng/ml with acceptable intra- and inter-day precision and accuracy. The intra-day and inter-day precisions were less than 10% and the accuracies of intra and inter-day assays were within the range of 97.20-104.83% and 98.8-102.2% respectively.
CONCLUSION: Based on the obtained results, a simple, accurate and precise reversed-phase isocratic HPLC method with UV detection has been optimized and validated for the determination of erlotinib hydrochloride in biological samples.

Entities:  

Keywords:  Erlotinib; HPLC; Protein binding; ultrafilteration

Year:  2013        PMID: 24312850      PMCID: PMC3848207          DOI: 10.5681/apb.2013.047

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  19 in total

1.  Rapid HPLC determination of pioglitazone in human plasma by protein precipitation and its application to pharmacokinetic studies.

Authors:  Ziba Islambulchilar; Hadi Valizadeh; Parvin Zakeri-Milani
Journal:  J AOAC Int       Date:  2010 May-Jun       Impact factor: 1.913

2.  A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.

Authors:  Lionel Faivre; Charline Gomo; Olivier Mir; Fabrice Taieb; Audrey Schoemann-Thomas; Stanislas Ropert; Michel Vidal; Daniel Dusser; Alain Dauphin; Francois Goldwasser; Benoit Blanchet
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-06-22       Impact factor: 3.205

Review 3.  Role of tyrosine kinase inhibitors in cancer therapy.

Authors:  Amit Arora; Eric M Scholar
Journal:  J Pharmacol Exp Ther       Date:  2005-07-07       Impact factor: 4.030

4.  Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Authors:  John R Johnson; Martin Cohen; Rajeshwari Sridhara; Yeh-Fong Chen; Gene M Williams; John Duan; Jogarao Gobburu; Brian Booth; Kimberly Benson; John Leighton; Li Shan Hsieh; Nallalerumal Chidambaram; Paul Zimmerman; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

5.  Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.

Authors:  Xin-Hua Xu; Jin Su; Xiang-Yang Fu; Feng Xue; Qiao Huang; Dao-Jun Li; Ming-Qian Lu
Journal:  Cancer Chemother Pharmacol       Date:  2010-09-16       Impact factor: 3.333

6.  Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.

Authors:  Jie Ling; Kim A Johnson; Zhuang Miao; Ashok Rakhit; Michael P Pantze; Marta Hamilton; Bert L Lum; Chandra Prakash
Journal:  Drug Metab Dispos       Date:  2005-12-28       Impact factor: 3.922

7.  Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.

Authors:  Gabriele Schaefer; Lihua Shao; Klara Totpal; Robert W Akita
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

8.  Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

Authors:  N A G Lankheet; M J X Hillebrand; H Rosing; J H M Schellens; J H Beijnen; A D R Huitema
Journal:  Biomed Chromatogr       Date:  2012-09-17       Impact factor: 1.902

9.  Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

Authors:  Charles M Rudin; Wanqing Liu; Apurva Desai; Theodore Karrison; Xuemin Jiang; Linda Janisch; Soma Das; Jacqueline Ramirez; Balasubramanian Poonkuzhali; Erin Schuetz; Donna Lee Fackenthal; Peixian Chen; Deborah K Armstrong; Julie R Brahmer; Gini F Fleming; Everett E Vokes; Michael A Carducci; Mark J Ratain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

10.  Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.

Authors:  Satheeshmanikandan R S Thappali; Kanthikiran Varanasi; Sridhar Veeraraghavan; Rambabu Arla; Sandhya Chennupati; Madheswaran Rajamanickam; Swaroop Vakkalanka; Mukkanti Khagga
Journal:  Sci Pharm       Date:  2012-06-18
View more
  3 in total

1.  A Simple, Fast, Low Cost, HPLC/UV Validated Method for Determination of Flutamide: Application to Protein Binding Studies.

Authors:  Sara Esmaeilzadeh; Hadi Valizadeh; Parvin Zakeri-Milani
Journal:  Adv Pharm Bull       Date:  2016-06-30

2.  Interactions Between Sirolimus and Anti-Inflammatory Drugs: Competitive Binding for Human Serum Albumin.

Authors:  Arash Khodaei; Soheila Bolandnazar; Hadi Valizadeh; Leila Hasani; Parvin Zakeri-Milani
Journal:  Adv Pharm Bull       Date:  2016-06-30

3.  Interaction of palmitic Acid with metoprolol succinate at the binding sites of bovine serum albumin.

Authors:  Mashiur Rahman; Farzana Prianka; Mohammad Shohel; Md Abdul Mazid
Journal:  Adv Pharm Bull       Date:  2014-08-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.